Innate and Adaptive Interleukin-22 Protects Mice from Inflammatory Bowel Disease
Top Cited Papers
Open Access
- 1 December 2008
- Vol. 29 (6), 947-957
- https://doi.org/10.1016/j.immuni.2008.11.003
Abstract
No abstract availableKeywords
Funding Information
- American Cancer Society
- American Liver Foundation
This publication has 49 references indexed in Scilit:
- IL-22 is required for Th17 cell–mediated pathology in a mouse model of psoriasis-like skin inflammationJournal of Clinical Investigation, 2008
- IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitisJournal of Clinical Investigation, 2008
- Interleukin-22 but Not Interleukin-17 Provides Protection to Hepatocytes during Acute Liver InflammationImmunity, 2007
- The Interleukin-22/STAT3 Pathway Potentiates Expression of Inducible Nitric-oxide Synthase in Human Colon Carcinoma CellsPublished by Elsevier ,2007
- Interleukin-23 drives innate and T cell–mediated intestinal inflammationThe Journal of Experimental Medicine, 2006
- IL-23 plays a key role inHelicobacter hepaticus–induced T cell–dependent colitisThe Journal of Experimental Medicine, 2006
- Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptidesThe Journal of Experimental Medicine, 2006
- Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brainNature, 2003
- IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesisJournal of Clinical Investigation, 1999
- Inhibition of Thl responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cellsImmunity, 1994